EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase

Wencke Walter iD, Niroshan Nadarajah, Stephan Hutter iD, Heiko Müller, Claudia Haferlach iD, Wolfgang Kern iD, Torsten Haferlach iD, Manja Meggendorfer iD

Leukemia · 2024-12 · 38 (12) · 2644-2652

DOI: 10.1038/s41375-024-02425-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia, online erschienen am 28.09.2024. Verfasst von Wencke Walter und 7 weiteren Autor:innen. Beteiligte Einrichtung: MLL Munich Leukemia Laboratory, Munich, Germany. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Blast Crisis, Mutation. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloproliferative neoplasms (MPN) are a heterogeneous group of clonal disorders characterized by aberrant hematopoietic proliferation and an intrinsic risk of progression to blast phase. The WHO classification 2022 identifies chronic myeloid leukemia and the BCR::ABL1 negative MPNs polycythemia vera, primary myelofibrosis and essential thrombocythemia as individual entities. However, overlaps, borderline findings or transitions between MPN subtypes occur and incomplete clinical data often complicates diagnosis. By conducting a thorough genetic analysis, we've developed a model that relies on 12 genetic markers to accurately stratify MPN patients. The model can be simplified into a decision tree for routine use. Comparing samples at chronic and blast phase revealed, that one third of patients lost their MPN driver-gene mutation, while mutations in splicing and chromatin modifying genes were stable, indicating a shared founder clone of chronic and blast phase with different driver mutations and therefore different progressing capacities. This was further supported by gain of typical de novo AML gene mutations, accompanied by gain of complex karyotypes and RAS pathway gene mutations. Our data suggest to perform a broader genetic screening at diagnosis and also at clinical progression, as driver mutations may change and the MPN-driver mutations present at diagnosis may disappear.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloproliferative DisordersBlast CrisisMutationHumansPrognosisDisease ProgressionMaleFemaleMiddle AgedAgedAdultBiomarkers, TumorCell Transformation, Neoplastic

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • MLL Munich Leukemia Laboratory, Munich, Germany.
  • MLL Munich Leukemia Laboratory, Munich, Germany. manja.meggendorfer@mll.com.

ORCID-Profile: Wencke Walter, Stephan Hutter, Claudia Haferlach, Wolfgang Kern, Torsten Haferlach, Manja Meggendorfer

Zitieren

APA

Walter, W., Nadarajah, N., Hutter, S., Müller, H., Haferlach, C., Kern, W., Haferlach, T., & Meggendorfer, M. (2024). Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase. Leukemia, 38(12), 2644-2652. https://doi.org/10.1038/s41375-024-02425-1

Vancouver

Walter W, Nadarajah N, Hutter S, Müller H, Haferlach C, Kern W, et al. Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase. Leukemia. 2024;38(12):2644-2652. doi:10.1038/s41375-024-02425-1

BibTeX
@article{Walter2024,
  author = {Walter, Wencke and Nadarajah, Niroshan and Hutter, Stephan and Müller, Heiko and Haferlach, Claudia and Kern, Wolfgang and Haferlach, Torsten and Meggendorfer, Manja},
  title = {Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase},
  journal = {Leukemia},
  year = {2024},
  volume = {38},
  number = {12},
  pages = {2644--2652},
  doi = {10.1038/s41375-024-02425-1}
}
Kostenlos starten →